Hiroshige Yoshioka
Koshigaya, 3438555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 171 publications
Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 04, 2026
Oncologic Safety of Omitting Mediastinal Lymph Node Dissection in Segmentectomy for Ground-Glass Opacity-Dominant Lung Cancer: A Supplementary Analysis of JCOG1211.
Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Published: March 15, 2026
Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 23, 2026
AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer.
Journal: Molecular therapy. Oncology
Published: January 08, 2026
Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.
Journal: Cancer science
Published: December 22, 2025
A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.
Journal: Therapeutic advances in medical oncology
Published: November 24, 2025
Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 18, 2025
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: September 09, 2025
Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan.
Journal: Respiratory investigation
Published: August 22, 2025
Last Updated: 09/26/2026